No headlines found.
Business Wire (Tue, 27-Jan 12:01 AM ET)
Business Wire (Wed, 14-Jan 8:00 AM ET)
REPEAT/MindWalk Advances Universal Influenza Program with a Breakthrough Functional Insight
Business Wire (Mon, 12-Jan 7:00 AM ET)
MindWalk Advances Universal Influenza Program with a Breakthrough Functional Insight
Business Wire (Fri, 9-Jan 8:01 PM ET)
MindWalk Reports Record Growth and Announces Strategic Progress on Its AI Asset Pipeline
Business Wire (Mon, 15-Dec 8:30 AM ET)
Business Wire (Mon, 8-Dec 8:30 AM ET)
MindWalk Holdings Corp is a Bio-Native AI company transforming drug discovery and development. Powered by patented HYFT technology and the LensAI platform, MindWalk unifies sequence, structure, function, and literature into a single computational language and closes the loop with an integrated, full-stack wet lab. The platform supports rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics that help turn insights into validated candidates at speed.
Mindwalk Holdings Corp. trades on the NASDAQ stock market under the symbol HYFT.
As of February 27, 2026, HYFT stock price declined to $1.14 with 120,881 million shares trading.
HYFT has a beta of 2.17, meaning it tends to be more sensitive to market movements. HYFT has a correlation of 0.04 to the broad based SPY ETF.
HYFT has a market cap of $53.23 million. This is considered a Micro Cap stock.
Last quarter Mindwalk Holdings Corp. reported $3 million in Revenue and -$.05 earnings per share. This fell short of revenue expectation by $-1 million and missed earnings estimates by -$.04.
HYFT support price is $1.12 and resistance is $1.26 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that HYFT shares will trade within this expected range on the day.